The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) is a huge mover today! About 1.08M shares traded hands. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 89.05% since April 18, 2016 and is uptrending. It has outperformed by 84.62% the S&P500.
The move comes after 5 months negative chart setup for the $10.55 billion company. It was reported on Nov, 18 by Barchart.com. We have $64.01 PT which if reached, will make NASDAQ:SGEN worth $949.50M less.
Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage
Out of 8 analysts covering Seattle Genetics (NASDAQ:SGEN), 5 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 63% are positive. Seattle Genetics has been the topic of 14 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The rating was maintained by RBC Capital Markets on Monday, September 14 with “Outperform”. Leerink Swann maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Friday, August 14. Leerink Swann has “Outperform” rating and $56 price target. The firm has “Neutral” rating by Piper Jaffray given on Friday, October 30. William Blair maintained the shares of SGEN in a report on Tuesday, August 25 with “Buy” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Outperform” rating by RBC Capital Markets on Friday, July 31. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Overweight” rating by Morgan Stanley on Wednesday, September 7. The rating was upgraded by Goldman Sachs on Thursday, September 15 to “Neutral”. Barclays Capital maintained the shares of SGEN in a report on Wednesday, July 27 with “Overweight” rating. RBC Capital Markets maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, October 10 with “Outperform” rating.
According to Zacks Investment Research, “Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRISÂ® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.09, from 0.91 in 2016Q1. The ratio increased, as 12 funds sold all Seattle Genetics, Inc. shares owned while 75 reduced positions. 34 funds bought stakes while 45 increased positions. They now own 136.24 million shares or 2.59% less from 139.87 million shares in 2016Q1.
Utah Retirement holds 0.02% or 17,500 shares in its portfolio. Millennium Mngmt Ltd Co reported 6,959 shares or 0% of all its holdings. Pnc Services Gp last reported 0% of its portfolio in the stock. Capstone Asset has invested 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Allianz Asset Mngmt Ag has invested 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Moreover, Pathstone Family Office Limited Liability Corp has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 330 shares. Guggenheim Cap Ltd Liability has 0.02% invested in the company for 134,823 shares. Raymond James Financial Svcs Advsrs Inc owns 6,184 shares or 0% of their US portfolio. Qs Investors Ltd Llc reported 11 shares or 0% of all its holdings. Citadel Ltd Liability Com, a Illinois-based fund reported 754,281 shares. Tributary Mngmt Limited Liability Co reported 50,700 shares or 0.3% of all its holdings. Zweig accumulated 46,250 shares or 0.19% of the stock. First City Management has 0.16% invested in the company for 5,350 shares. Redmile Group Ltd Co owns 1.38M shares or 5.33% of their US portfolio. Envestnet Asset Mngmt has 8,018 shares for 0% of their US portfolio.
Insider Transactions: Since May 23, 2016, the stock had 4 insider buys, and 24 selling transactions for $110.15 million net activity. SIEGALL CLAY B sold $529,007 worth of stock. $141,617 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares were sold by Cline Darren S. DRACHMAN JONATHAN G also sold $517,379 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, November 9. BAKER FELIX bought $57.85M worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Tuesday, November 1. $252,102 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares were sold by DOBMEIER ERIC. $185,943 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares were sold by SIMPSON TODD E. 3,991 shares were sold by HIMES VAUGHN B, worth $185,943 on Monday, August 22.
More recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Fool.com which released: “5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on Pipeline” on October 31, 2016. Also Businesswire.com published the news titled: “Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS …” on November 10, 2016. 247Wallst.com‘s news article titled: “Massive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife …” with publication date: November 13, 2016 was also an interesting one.
SGEN Company Profile
Seattle Genetics, Inc., incorporated on July 15, 1997, is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. It also has multiple preclinical and research-stage programs that employ its technologies.